CRL - Charles River Laboratories International, Inc.
After hours:
| Previous close | 194.89 |
| Open | 195.28 |
| Bid | 186.73 x 800 |
| Ask | 305.00 x 800 |
| Day's range | 193.73 - 197.13 |
| 52-week range | 181.22 - 262.00 |
| Volume | |
| Avg. volume | 561,401 |
| Market cap | 9.936B |
| Beta (5Y monthly) | 1.34 |
| PE ratio (TTM) | 20.50 |
| EPS (TTM) | 9.47 |
| Earnings date | 01 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 249.00 |
ZacksHere's Why You Should Retain Charles River (CRL) Stock Now
Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.
Simply Wall St.Declining Stock and Solid Fundamentals: Is The Market Wrong About Charles River Laboratories International, Inc. (NYSE:CRL)?
It is hard to get excited after looking at Charles River Laboratories International's (NYSE:CRL) recent performance...
ZacksCharles River (CRL) Q1 Earnings Top Estimates, View Narrowed
Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.
ZacksCharles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ZacksCharles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
Charles River (CRL) delivered earnings and revenue surprises of 7.34% and 4.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireCharles River Laboratories Announces First-Quarter 2023 Results
WILMINGTON, Mass., May 11, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 12.6% from $913.9 million in the first quarter of 2022.
ZacksCharles River (CRL) to Report Q1 Earnings: What's in Store?
Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
Business WireCharles River Laboratories Launches Next Generation Sequencing Services for Bacterial Identification and Fungal ID
WILMINGTON, Mass., May 01, 2023--Charles River launches Accugenix NGS for bacterial identification and fungal ID; announces partner lab initiative to expand global coverage.
Business WireCharles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call
WILMINGTON, Mass., April 11, 2023--Charles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call
Business WireCharles River Laboratories Showcases End-to-End Oncology Capabilities at AACR 2023
WILMINGTON, Mass., April 10, 2023--Charles River highlights the importance of next-generation technologies for oncology drug discovery at AACR 2023.
- Simply Wall St.
Calculating The Fair Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
Key Insights Charles River Laboratories International's estimated fair value is US$212 based on 2 Stage Free Cash Flow...
ZacksWhy Is Charles River (CRL) Down 14.8% Since Last Earnings Report?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
The total return for Charles River Laboratories International (NYSE:CRL) investors has risen faster than earnings growth over the last five years
It might be of some concern to shareholders to see the Charles River Laboratories International, Inc. ( NYSE:CRL...
- Zacks
Charles River's (CRL) New Cloud Platform Offers Real-Time Data
Charles River (CRL) launches cloud-based platform Apollo which enhances decision making abilities by providing real-time Toxicology study data.
ZacksCharles River (CRL) Advances CDMO Portfolio With Latest Offer
Charles River's (CRL) newest addition, pHelper plasmid, targets simplifying the complex supply chains and cutting production timelines.
Business WireCharles River Laboratories to Present at Barclays Global Healthcare Conference
WILMINGTON, Mass., March 13, 2023--Charles River Laboratories To Present At Barclays Global Healthcare Conference
Business WireCharles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data
WILMINGTON, Mass., March 13, 2023--Charles River launches Apollo, an intuitive customer platform that provides secure cloud-based access to real-time toxicology study data.
Business WireCharles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing
WILMINGTON, Mass., March 09, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing. It is available immediately in Research Grade (RG), High Quality (HQ), and Good Manufacturing Practice (GMP)-grade.
- Simply Wall St.
Richard Wallman Is The Independent Director of Charles River Laboratories International, Inc. (NYSE:CRL) And They Just Picked Up 9.1% More Shares
Investors who take an interest in Charles River Laboratories International, Inc. ( NYSE:CRL ) should definitely note...
- Simply Wall St.
Charles River Laboratories International Full Year 2022 Earnings: Beats Expectations
Charles River Laboratories International ( NYSE:CRL ) Full Year 2022 Results Key Financial Results Revenue: US$3.98b...
ZacksCharles River (CRL) Q4 Earnings Top Estimates, Margins Dip
Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.
ZacksCharles River Laboratories (CRL) Q4 Earnings and Revenues Beat Estimates
Charles River (CRL) delivered earnings and revenue surprises of 8.36% and 5.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireCharles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
WILMINGTON, Mass., February 22, 2023--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
Business WireCharles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
WILMINGTON, Mass. & CAMBRIDGE, Mass., February 16, 2023--Charles River and Pioneering Medicines enter agreement to deploy Logica to create optimized small molecules that will lead to novel therapies.
Business WireCharles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
WILMINGTON, Mass., February 15, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.